Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis

REFERENCES

1. 1.↵
   1. Taba P,
   2. Rosenthal M,
   3. Habicht J,
   4. Tarien H,
   5. Mathiesen M,
   6. Hill S,
   7. et al.

   Barriers and facilitators to the implementation of clinical practice guidelines: a cross-sectional survey among physicians in Estonia. BMC Health Serv Res 2012;12:455.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Volkmann ER,
   2. Chung A,
   3. Tashkin DP

   . Managing systemic sclerosis-related interstitial lung disease in the modern treatment era. J Scleroderma Relat Disord 2017;2:72–83.

   OpenUrl
3. 3.↵
   1. Kowal-Bielecka O,
   2. Fransen J,
   3. Avouac J,
   4. Becker M,
   5. Kulak A,
   6. Allanore Y,
   7. et al;
   8. EUSTAR Coauthors

   . Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327–39.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Kowal-Bielecka O,
   2. Landewe R,
   3. Avouac J,
   4. Chwiesko S,
   5. Miniati I,
   6. Czirjak L,
   7. et al;
   8. EUSTAR Co-Authors

   . EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620–8.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Pellar RE,
   2. Pope JE

   . Evidence-based management of systemic sclerosis: navigating recommendations and guidelines. Sem Arthritis Rheum 2017;46:767–74.

   OpenUrl
6. 6.↵
   1. Muller-Ladner U,
   2. Tyndall A,
   3. Czirjak L,
   4. Denton C,
   5. Matucci-Cerinic M

   . Ten years EULAR Scleroderma Research and Trials (EUSTAR): what has been achieved? Ann Rheum Dis 2014;73:324–7.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Proudman SM,
   2. Stevens W,
   3. Wilson ME,
   4. Sahhar J,
   5. Hudson M,
   6. Pope J,
   7. et al.

   What have multicentre registries across the world taught us about the disease features of systemic sclerosis? J Scleroderma Relat Disord 2017;2:169–82.

   OpenUrl
8. 8.↵
   1. Birrenbach T,
   2. Kraehenmann S,
   3. Perrig M,
   4. Berendonk C,
   5. Huwendiek S

   . Physicians’ attitudes toward, use of, and perceived barriers to clinical guidelines: a survey among Swiss physicians. Adv Med Educ Pract 2016;7:673–80.

   OpenUrl
9. 9.↵
   1. Cabana MD,
   2. Rand CS,
   3. Powe NR,
   4. Wu AW,
   5. Wilson MH,
   6. Abboud PA,
   7. et al.

   Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458–65.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Walker KM,
    2. Pope J;
    3. Scleroderma Clinical Trials Consortium;
    4. Canadian Scleroderma Research Group

    . Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 2011;38:1326–8.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Vidal C,
    2. Ruano C,
    3. Bernardino V,
    4. Lavado P,
    5. Lladó A,
    6. Santos M,
    7. et al.

    EUSTAR registration impacts favourably on clinical practice. J Scleroderma Relat Disord 2017;2:e4.

    OpenUrl
12. 12.↵
    1. Ingegnoli F,
    2. Schioppo T,
    3. Allanore Y,
    4. Caporali R,
    5. Colaci M,
    6. Distler O,
    7. et al.

    Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Sem Arthritis Rheum 2019;48:686–93.

    OpenUrl
13. 13.↵
    1. Guyatt G,
    2. Oxman AD,
    3. Akl EA,
    4. Kunz R,
    5. Vist G,
    6. Brozek J,
    7. et al.

    GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383–94.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Coleiro B,
    2. Marshall SE,
    3. Denton CP,
    4. Howell K,
    5. Blann A,
    6. Welsh KI,
    7. et al.

    Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001;40:1038–43.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Spierings J,
    2. van Rhijn-Brouwer FCC,
    3. van Laar JM

    . Hematopoietic stem-cell transplantation in systemic sclerosis: an update. Curr Opin Rheumatol 2018;30:541–7.

    OpenUrl
16. 16.↵
    1. Denoeud L,
    2. Mazieres B,
    3. Payen-Champenois C,
    4. Ravaud P

    . First line treatment of knee osteoarthritis in outpatients in France: adherence to the EULAR 2000 recommendations and factors influencing adherence. Ann Rheum Dis 2005;64:70–4.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Herrick AL

    . Controversies on the use of steroids in systemic sclerosis. J Scleroderma Relat Disord 2017;2:84–91.

    OpenUrl
18. 18.↵
    1. Herrick AL,
    2. Gallas A

    . Systemic sclerosis-related calcinosis. J Scleroderma Relat Disord 2016;1:194–203.

    OpenUrl
19. 19.↵
    1. Khanna D,
    2. Distler JH,
    3. Sandner P,
    4. Distler O

    . Emerging strategies for treatment of systemic sclerosis. J Scleroderma Relat Disord 2016;1:186–93.

    OpenUrl